NCT06401980View on ClinicalTrials.gov

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

June 30, 2030

Study Completion Date

September 30, 2030

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Darolutamide

Darolutamide will be supplied in bottles as 300 mg film-coated tablets for oral intake

OTHER

Standard of care

"* Docetaxel~* Cabazitaxel~* LuPSMA~* Radium 223~* Olaparib, in case of BRCA1 or 2 mutated or HRR deficient tumors~The standard of care is chosen by the local investigator and respecting the country specific approvals."

Trial Locations (13)

1211

RECRUITING

Hôpitaux Universitaires Genève HUG, Geneva

5000

RECRUITING

Tumorzentrum Aarau TZA, Aarau

5404

RECRUITING

Kantonsspital Baden, Baden

6004

RECRUITING

Luzerner Kantonsspital, Lucerne

6500

RECRUITING

Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

7000

RECRUITING

Kantonsspital Graubuenden, Chur

8038

RECRUITING

OnkoZentrum Zürich - Standort Seefeld, Zurich

8063

RECRUITING

Stadtspital Triemli Zürich, Zurich

8091

RECRUITING

UniversitaetsSpital Zuerich, Zurich

8401

RECRUITING

Kantonsspital Winterthur, Winterthur

Unknown

RECRUITING

Inselspital, Bern

RECRUITING

Kantonsspital St. Gallen, Sankt Gallen

CH-1011

RECRUITING

Centre Hospitalier Universitaire Vaudois CHUV, Lausanne

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER